{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:07:28Z","timestamp":1790676448706,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T00:00:00Z","timestamp":1555372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00262-019-02341-9","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T20:06:36Z","timestamp":1555445196000},"page":"983-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["MHC class-I downregulation in PD-1\/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series"],"prefix":"10.1007","volume":"68","author":[{"given":"Selma","family":"Ugurel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelina","family":"Spassova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Drusio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Cherouny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Melior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Sucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrin","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-653X","authenticated-orcid":false,"given":"J\u00fcrgen C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,16]]},"reference":[{"key":"2341_CR1","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"Becker JC, Stang A, Decaprio JA, Cerroni L, Lebb\u00e9 C, Veness M, Nghiem P (2017) Merkel cell carcinoma. Nat Rev Dis Prim 3:17077. \n                    https:\/\/doi.org\/10.1038\/nrdp.2017.77","journal-title":"Nat Rev Dis Prim"},{"key":"2341_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000363","author":"P Terheyden","year":"2017","unstructured":"Terheyden P, Becker JC (2017) New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol. \n                    https:\/\/doi.org\/10.1097\/CCO.0000000000000363","journal-title":"Curr Opin Oncol"},{"key":"2341_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40425-017-0310-x","volume":"6","author":"HL Kaufman","year":"2018","unstructured":"Kaufman HL, Russell JS, Hamid O, Bhatia S, Terheyden P, D\u2019Angelo SP, Shih KC, Lebb\u00e9 C, Milella M, Brownell I, Lewis KD, Lorch JH, von Heydebreck A, Hennessy M, Nghiem P (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after\u2009\u2265\u20091\u00a0year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer 6:7. \n                    https:\/\/doi.org\/10.1186\/s40425-017-0310-x","journal-title":"J Immunother Cancer"},{"key":"2341_CR4","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, Berry S, Chartash EK, Daud A, Fling SP, Friedlander PA, Kluger HM, Kohrt HE, Lundgren L, Margolin K, Mitchell A, Olencki T, Pardoll DM, Reddy SA, Shantha EM, Sharfman WH, Sharon E, Shemanski LR, Shinohara MM, Sunshine JC, Taube JM, Thompson JA, Townson SM, Yearley JH, Topalian SL, Cheever MA (2016) PD-1 Blockade with pembrolizumab in advanced Merkel cell carcinoma. N Engl J Med 374:2542\u20132552. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1603702","journal-title":"N Engl J Med"},{"key":"2341_CR5","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1158\/2326-6066.CIR-14-0005","volume":"2","author":"KG Paulson","year":"2014","unstructured":"Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, Koba S, Thibodeau R, Nagase K, Simonson WT, Seo A, Koelle DM, Madeleine M, Bhatia S, Nakajima H, Sano S, Hardwick JS, Disis ML, Cleary MA, Becker JC, Nghiem P (2014) Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res 2:1071\u20131079. \n                    https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0005","journal-title":"Cancer Immunol Res"},{"key":"2341_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-02608-0","volume":"7","author":"C Ritter","year":"2017","unstructured":"Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC (2017) Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep 7:1. \n                    https:\/\/doi.org\/10.1038\/s41598-017-02608-0","journal-title":"Sci Rep"},{"key":"2341_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2283-0","author":"D Llopiz","year":"2018","unstructured":"Llopiz D, Ruiz M, Villanueva L, Iglesias T, Silva L, Egea J, Lasarte JJ, Pivette P, Trochon-Joseph V, Vasseur B, Dixon G, Sangro B, Sarobe P (2018) Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor belinostat in a murine hepatocellular carcinoma model. Cancer Immunol Immunother. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2283-0","journal-title":"Cancer Immunol Immunother"},{"key":"2341_CR8","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2010.30.6308","volume":"29","author":"KG Paulson","year":"2011","unstructured":"Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, Schrama D, Simonson WT, Lemos BD, Byrd DR, Koelle DM, Galloway DA, Leonard JH, Madeleine MM, Argenyi ZB, Disis ML, Becker JC, Cleary MA, Nghiem P (2011) Transcriptome-wide studies of Merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 29:1539\u20131546. \n                    https:\/\/doi.org\/10.1200\/JCO.2010.30.6308","journal-title":"J Clin Oncol"},{"key":"2341_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1309\/AJCPIKDZM39CRPNC","volume":"142","author":"KG Paulson","year":"2014","unstructured":"Paulson KG, Iyer JG, Simonson WT, Blom A, Thibodeau RM, Schmidt M, Pietromonaco S, Sokil M, Warton EM, Asgari MM, Nghiem P (2014) CD8+ lymphocyte intratumoral infiltration as a stage-independent predictor of merkel cell carcinoma survival. Am J Clin Pathol 142:452\u2013458. \n                    https:\/\/doi.org\/10.1309\/AJCPIKDZM39CRPNC","journal-title":"Am J Clin Pathol"},{"key":"2341_CR10","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/jid.2011.115","volume":"131","author":"D Schrama","year":"2011","unstructured":"Schrama D, Peitsch WK, Zapatka M, Kneitz H, Houben R, Eib S, Haferkamp S, Moore PS, Shuda M, Thompson JF, Trefzer U, Pf\u00f6hler C, Scolyer RA, Becker JC (2011) Merkel cell polyomavirus status is not associated with clinical course of Merkel cell carcinoma. J Investig Dermatol 131:1631\u20131638. \n                    https:\/\/doi.org\/10.1038\/jid.2011.115","journal-title":"J Investig Dermatol"},{"key":"2341_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2285-y","author":"M Maio","year":"2018","unstructured":"Maio M, Coukos G, Ferrone S, Fox BA, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, R\u00fcttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R (2018) Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer Immunol Immunother. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2285-y","journal-title":"Cancer Immunol Immunother"},{"key":"2341_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3390\/cancers10020032","volume":"10","author":"S Abdin","year":"2018","unstructured":"Abdin S, Zaher D, Arafa E-S, Omar H (2018) Tackling cancer resistance by immunotherapy: updated clinical impact and safety of PD-1\/PD-L1 inhibitors. Cancers 10:32. \n                    https:\/\/doi.org\/10.3390\/cancers10020032","journal-title":"Cancers"},{"key":"2341_CR13","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","volume":"67","author":"L Cai","year":"2018","unstructured":"Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S (2018) Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother 67:999\u20131009. \n                    https:\/\/doi.org\/10.1007\/s00262-018-2131-2","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2341_CR14","doi-asserted-by":"publisher","first-page":"e1414","DOI":"10.3390\/ijms18071414","volume":"18","author":"T Eckschlager","year":"2017","unstructured":"Eckschlager T, Plch J, Stiborova M, Hrabeta J (2017) Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci 18(7):e1414. \n                    https:\/\/doi.org\/10.3390\/ijms18071414","journal-title":"Int J Mol Sci"},{"key":"2341_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.3807","author":"PS Suresh","year":"2017","unstructured":"Suresh PS, Devaraj VC, Srinivas NR, Mullangi R (2017) Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomed Chromatogr. \n                    https:\/\/doi.org\/10.1002\/bmc.3807","journal-title":"Biomed Chromatogr"},{"key":"2341_CR16","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pag\u00e8s F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39:782\u2013795. \n                    https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003","journal-title":"Immunity"},{"key":"2341_CR17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer\u2013immune set point. Nature 541:321\u2013330. \n                    https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02341-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02341-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T23:04:09Z","timestamp":1586905449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02341-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,16]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["2341"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02341-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,16]]},"assertion":[{"value":"10 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Selma Ugurel declares research support from medac and Bristol-Myers Squibb, speakers and advisory board honoraria from Bristol-Myers Squibb, Merck Sharp & Dome, and Roche, and travel support from Bristol-Myers Squibb, medac, Merck Sharp & Dome, and Roche. Jonas Wohlfarth is an intern at 4SC. Lisa Zimmer has served as consultant or\/and has received honoraria from Roche, Bristol-Myers Squibb, Merck Sharp & Dome, GlaxoSmithKline, Novartis, Merck Serono, and travel support from Merck Sharp & Dome, Bristol-Myers Squibb, Amgen and Novartis. Dirk Schadendorf has received speaker honoraria from Roche, Novartis, Bristol-Myers Squibb, Merck Sharp & Dome, Amgen, Merck Serono and Pierre-Fabre, advisory board honoraria from Roche, Novartis, Bristol-Myers Squibb, Merck Sharp & Dome, Amgen, Incyte, Merck Serono and Pierre-Fabre as well as research funding from Novartis and Bristol-Myers Squibb. J\u00fcrgen C. Becker has received speaker honoraria from Amgen, Merck Serono, and Pfizer, advisory board honoraria from Amgen, CureVac, eTheRNA, Lytix, Merck Serono, Novartis, Rigontec, and Takeda as well as research funding from Alcedis, Boehringer Ingelheim, Bristol-Myers Squibb, and Merck Serono; he also received travel support from 4SC and Incyte. The authors declare that there is no other conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The investigational procedures were approved by the institutional review board\/ethic committee (17-7539-BO; Ethics Committee of the University Duisburg-Essen).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients provided informed consent for the scientific work up of the tumor biopsies as well as for the publication of the results in an anonymized way.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}